–The below is a company sponsored announcement–
ASX cannabis stocks are gaining momentum, stimulated by significant developments in the global regulatory environments in recent months.
On the cusp of a potential rerate is $29M capped Neurotech International Limited ((NTI)), a stock with imminent news flow.
NTI is a medical cannabis company focused on the clinical applications of unique cannabis strains to treat neurological disorders.
The last month has been an extremely rewarding period for the company, with stage 1 clinical product formulation and development studies commencing in mid-November, and an outlook to enter into clinical trials in the March quarter of 2021.